2024 Volume 2 Pages 32-38
Introduction: In this study, we investigated the association between serum biomarkers and skeletal muscle function in patients with advanced or recurrent lung or pancreatic cancer.
Methods: This single-center retrospective cohort study included patients with lung or pancreatic cancer before the administration of chemotherapy. In addition to basic information, we recorded serum biomarker levels (interleukin [IL]-6, tumor necrosis factor [TNF]-α, and insulin-like growth factor [IGF]-1) and skeletal muscle function indicators (skeletal muscle mass index [SMI], lean body mass [LBM], and grip strength). A linear regression analysis was performed after a univariate regression analysis with skeletal muscle function as the dependent variable and serum biomarkers as independent variables.
Results: The study included 17 patients. The univariate regression analysis revealed a significant association between TNF-α and grip strength (p = 0.0134), IGF-1 and SMI (p = 0.0175), and IGF-1 and LBM (p = 0.0152). This significant association between TNF-α and grip strength persisted despite the adjustment for confounders. Notably, the significant association between IGF-1 and SMI as well as between IGF-1 and LBM persisted despite the adjustment for confounders other than age. In contrast, serum IL-6 level was not significantly associated with skeletal muscle function.
Conclusion: Serum TNF-α and IGF-1 levels were associated with skeletal muscle function in patients with advanced or recurrent lung or pancreatic cancer.
